Trial Profile
A phase I/II trial of CJC 1134 as a single dose in patients with stable type 2 diabetes mellitus who were receiving metformin therapy.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 15 Feb 2007
Price :
$35
*
At a glance
- Drugs Albenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors ConjuChem
- 15 Feb 2007 Status change
- 16 Oct 2006 Status change
- 14 Feb 2006 New trial record.